Evidence map›Paper›PMID 22019759›Full record

ArticleActa biomaterialia2012

Controlled release of vascular endothelial growth factor using poly-lactic-co-glycolic acid microspheres: in vitro characterization and application in polycaprolactone fumarate nerve conduits.

Jing Rui, Mahrokh Dadsetan, M Brett Runge, Robert J Spinner, Michael J Yaszemski, Anthony J Windebank, Huan Wang

Abstract read
In one paragraph

Article in Acta biomaterialia, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Article
  2. Review
  3. Injectable neural hydrogel asRegenerative engineering and translational medicine · 2023
    Article
  4. Review
  5. Article
  6. The synthetic artificial stem cell (SASC): Shifting the paradigm of cell therapy in regenerative engineering.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. [Advance of vascularization of tissue engineered peripheral nerve].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2019
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jing RuiDepartment of Neurological Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Mahrokh Dadsetan
M Brett Runge
Robert J Spinner
Michael J Yaszemski
Anthony J Windebank
Huan Wang

Funding

Musculoskeletal Research Training ProgramT32AR056950 · NIAMS · MAYO CLINIC ROCHESTER · PI Jennifer J Westendorf · 2009 to 2026
$7.0M
NIAMS NIH HHS 1T32AR056950-01NIAMS NIH HHS T32 AR056950
6 · The paper itself

Abstract

Vascular endothelial growth factor (VEGF) is a potent angiogenic stimulator. Controlled release of such stimulators may enhance and guide the vascularization process, and when applied in a nerve conduit may play a role in nerve regeneration. We report the fabrication and in vitro characterization of poly-lactic-co-glycolic acid (PLGA) microspheres encapsulating VEGF and the in vivo application of nerve conduits supplemented with VEGF-containing microspheres. PLGA microspheres containing VEGF were prepared by the double emulsion-solvent evaporation technique. This yielded 83.16% of microspheres with a diameter <53 μm. VEGF content measured by ELISA indicated 93.79±10.64% encapsulation efficiency. Release kinetics were characterized by an initial burst release of 67.6±8.25% within the first 24h, followed by consistent release of approximately 0.34% per day for 4 weeks. Bioactivity of the released VEGF was tested by human umbilical vein endothelial cell (HUVEC) proliferation assay. VEGF released at all time points enhanced HUVEC proliferation, confirming that VEGF retained its bioactivity throughout the 4 week time period. When the microsphere delivery system was placed in a biosynthetic nerve scaffold robust nerve regeneration was observed. This study established a novel system for controlled release of growth factors and enables in vivo studies of nerve conduits conditioned with this system.

Indexed as

MicrospheresAnimalsCell ProliferationDelayed-Action PreparationsDrug CompoundingGuided Tissue RegenerationHumansHuman Umbilical Vein Endothelial CellsKineticsLactic AcidMicroscopy, Electron, ScanningNerve RegenerationParticle SizePolyestersPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerDelayed-Action PreparationsLactic Acidpolycaprolactonepoly(caprolactone fumarate)PolyestersPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerVascular Endothelial Growth Factor A

Identifiers

PMID22019759
PMCPMC3972821

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.